Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma
Loretta J. Nastoupil, Sattva S. Neelapu, R. Eric Davis, Felipe Samaniego, Nathan Fowler, Jason R. Westin, Hun Ju Lee, Michael Wang, Fredrick B. Hagemeister, Alexander Cecil, James Dow, Kemal Haque, Franck A. Silva, Andrew Whale, Letitia Lensun, Elisabeth A. Bone, Hilary McElwaine-Johnn, Philip Beer
Abstract
= 3).
Topics & Concepts
Mantle cell lymphomaMedicineRashLymphomaAdverse effectChronic lymphocytic leukemiaInternal medicineIbrutinibGastroenterologyRefractory (planetary science)Follicular lymphomaCancer researchOncologyLeukemiaBiologyAstrobiologyLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchViral-associated cancers and disorders